Secondary hypertension Medical Services in China

Secondary hypertension is a form of high blood pressure caused by an underlying, identifiable condition—such as renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing’s syndrome, or coarctation of the aorta. Unlike essential hypertension, it accounts for approximately 5–10% of all hypertension cases and often presents earlier in life, with more severe or resistant blood pressure elevation. Accurate diagnosis requires comprehensive evaluation: hormonal assays (e.g., plasma renin activity, aldosterone-to-renin ratio), imaging (CT/MRI angiography, adrenal vein sampling), and functional testing. Timely identification and targeted intervention—whether pharmacologic, endovascular (e.g., renal artery stenting), or surgical (e.g., adrenalectomy)—can normalize blood pressure and prevent end-organ damage.

China offers distinct advantages for international patients seeking secondary hypertension management. Leading cardiovascular centers—such as Fu Wai Hospital (National Center for Cardiovascular Diseases) and Shanghai Ruijin Hospital—combine deep subspecialty expertise in hypertension and endocrine-cardiovascular interface disorders with cutting-edge technology, including 3T MRI, digital subtraction angiography, and minimally invasive robotic-assisted adrenalectomy. Clinical outcomes reflect this: over 85% of eligible patients with unilateral primary aldosteronism achieve biochemical cure and significant BP reduction post-adrenalectomy; renal artery revascularization success rates exceed 92% in experienced centers. Treatment costs remain 40–60% lower than in the US or Western Europe, without compromising evidence-based protocols or multidisciplinary care standards.

As a dedicated medical tourism agency, we facilitate seamless access to these resources—vetting accredited hospitals, coordinating specialist consultations, arranging visa support and accommodation, and providing transparent, all-inclusive pricing upfront. Our clinical coordinators guide patients through diagnostic workup, treatment planning, and follow-up, ensuring continuity and clarity at every stage.

Treatment Options & Itemized Cost Breakdown: Secondary Hypertension (Cardiovascular Department)

Non-Surgical / Conservative Management

*Target Criteria:* Confirmed secondary cause (e.g., renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing’s syndrome) with mild–moderate hemodynamic impact; stable organ function; contraindications or patient refusal for intervention.

• •Diagnostic Workup (Pre-Treatment)

- Plasma renin activity + aldosterone (ARR): $35–$50 - 24-hr urinary metanephrines: $75–$95 - Cortisol rhythm (8 AM/4 PM salivary cortisol + DST): $60–$85 - Contrast-enhanced CT angiography (renal/adrenal): $180–$240

• •Pharmacotherapy (Monthly, Tiered)

- *Tier 2 (Add-on control)*: Calcium channel blockers, beta-blockers, low-dose thiazides: $8–$18 - *Tier 3 (Resistant cases)*: Hydralazine + isosorbide dinitrate, clonidine: $15–$30

Surgical / Interventional Procedures

*Eligibility Criteria:* Hemodynamically significant unilateral adrenal adenoma (confirmed by AV sampling), >70% renal artery stenosis with hypertension uncontrolled on ≥3 drugs + renal impairment, biochemically confirmed pheochromocytoma with resectable tumor.

• •Adrenalectomy (Laparoscopic, PA or Pheo)

- Procedure + anesthesia + 3-day hospital stay: $2,800–$3,600

• •Renal Artery Stenting (Endovascular)

- Procedure (stent + angiography + 2-day admission): $3,100–$4,200

• •Bilateral Adrenal Vein Sampling (AVS)

Special/Complex Condition Management

• •Fibromuscular dysplasia (FMD)-related RAS: Medical therapy preferred; angioplasty only if refractory: $2,400–$3,300
• •Coarctation of aorta (adult presentation): Cardiac MRI + catheter-based stenting: $4,800–$6,200
• •Malignant hypertension with acute kidney injury: ICU admission + IV nicardipine/labetalol + dialysis support: $1,200–$2,000/day

Quick Selection Guide

• •<45 years, confirmed unilateral aldosteronism, no comorbidities: Laparoscopic adrenalectomy ($3,200 avg) — curative intent, optimal long-term cost.
• •65+ years, bilateral RAS + CKD stage 3, limited mobility: Optimized medical therapy ($20–$45/month) — avoids procedural risk; monitor eGFR quarterly.
• •Budget-constrained (<$500 total): Prioritize ARR + renal Doppler ($80–$115) to confirm PA or RAS; initiate spironolactone or ACEi ($12–$25/month) while deferring imaging.
• •Severe resistant HTN + acute LV dysfunction: Urgent cardiac echo + renal angiography ($275) → proceed to stenting ($3,650 avg) if >70% stenosis confirmed.